For the quarter ending 2026-03-31, NRXPW had -$1,084K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents at beginning of period | - | - | 1,443 | - |
| Net loss | -1,430 | 360 | -5,890 | -23,092 |
| Depreciation and amortization expense | 63 | 42 | 28 | - |
| Amortization of operating right of use assets | 102 | 58 | 15 | - |
| Warrant issuance costs related to alvogen termination | - | 0 | 0 | 0 |
| Stock-based compensation | 151 | 81 | 68 | 79 |
| Convertible note default penalty | - | 0 | 0 | 0 |
| Provision (recovery) for expected credit losses | 28 | 40 | - | - |
| Common stock issued in exchange for services | - | 1 | 450 | 150 |
| Change in fair value of warrant liabilities | -3,538 | -3,555 | 4,963 | 3,518 |
| Change in fair value of convertible promissory notes | 0 | -4,093 | 8,032 | - |
| Depreciation expense | - | - | - | 0 |
| Loss on convertible note conversions | 0 | -1,962 | -772 | -3,467 |
| Insurance loan payable | - | - | 0 | 0 |
| Gain on exercise of warrant liabilities | - | 0 | 5,369 | - |
| Loss on issuance of registered direct common stock | 0 | 0 | -1 | -729 |
| Loss on consideration shares and warrants | 0 | 0 | 0 | -1,277 |
| Change in fair value of convertible note payable | - | - | - | 6,530 |
| Loss on equity method investments | 2 | -35 | - | - |
| Expense for debt issuance costs due to fair value election on anson notes | 0 | 0 | 0 | 350 |
| Prepaid expense and other assets | -420 | -451 | -227 | -187 |
| Account receivable | 48 | -36 | -12 | - |
| Accounts payable | 129 | 13 | 601 | -501 |
| Operating lease liabilities | -102 | -55 | -63 | - |
| Accrued expense and other liabilities | -68 | 913 | -210 | -202 |
| Net cash used in operating activities | -4,295 | -3,713 | -2,891 | -7,508 |
| Business acquisition, net of cash acquired | - | -183 | 2,561 | - |
| Cash used in investments | 213 | 432 | - | - |
| Net cash used in investing activities | -213 | -249 | -2,561 | - |
| Proceeds from issuance of insurance loan | - | 0 | -225 | 452 |
| Repayment of convertible note | - | 0 | 0 | 0 |
| Proceeds from anson convertible note, net | - | 0 | 0 | 5,000 |
| Repayment of insurance note | 0 | 154 | 0 | 394 |
| Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs | - | 0 | 0 | 0 |
| Proceeds from liability classified warrants | - | 3,087 | 0 | - |
| Expense for debt issuance costs due to fair value election on anson notes | 0 | 0 | 0 | 350 |
| Atm offering, net of offering costs | 3,424 | 1,641 | 3,739 | 1,012 |
| Proceeds from issuance of common stock and warrants, net of issuance costs-Consideration Warrants | 0 | 0 | 6,213 | 3,255 |
| Proceeds from issuance of common stock and warrants, net of issuance costs-Warrants Other Than Consideration Warrants | 0 | 0 | 0 | 0 |
| Net cash provided by financing activities | 3,424 | 4,575 | 9,726 | 8,975 |
| Net increase (decrease) in cash and cash equivalents | -1,084 | 613 | 4,274 | 1,467 |
| Cash and cash equivalents at beginning of year | 7,797 | 7,200 | - | - |
| Cash and cash equivalents at end of period | - | - | 7,200 | - |
| Cash and cash equivalents at end of year | 6,713 | 7,797 | - | - |
NRX Pharmaceuticals, Inc. (NRXPW)
NRX Pharmaceuticals, Inc. (NRXPW)